Drug Profile
Research programme: polyclonal antibody therapeutics - Fresh Tracks Therapeutics
Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics
- Class Polyclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ebola virus infections